Potential Partners

Analysing the recent reports of B Cell vs T Cell Immunology Therapy; I've doing a bit of research on my own.

Now, before I continue I do wish to provide a disclaimer here that this is simply my very own opinion and should not be considered professional advice.

I think Imugene has set the bar quite high in terms of upholding clinical trial standards, a remarkable team that consists of credible Scientists and a Management Team with a tremendous background in the Biotech Space.

Based on my analysis; if and when a Partnership does happen after IMU releases their findings. I believe there's definitely an opportunity here between GSK and Johnson and Johnson.

Firstly, Dr. Axel Hoos has a remarkable reputation with GSK; his work at GSK would undoubtedly lead him to be the first to propose the opportunity (if they haven't already) for a potential partnership of this scale.

Johnson and Johnson, on the other hand, is the largest BioTech Company in terms of Market-Cap and it's no secret they've been trying to break into the Immunology space. This could be a huge break for them if they decide to team up with IMU.

Regardless of the partnership, it looks to me as though the days of a potential partnership don't seem too far off anymore. Just a matter of raising awareness for IMU and that would be a task definitely left up to Leslie's Leadership.

Upcoming Release of Clinical Trial Data with an added boost of raising IMU's Market Cap, we could see a potentially lucrative deal being formed.

Sources:
https://journalhealthcare.com/17794...-symptoms-treatment-includes-and-latest-news/

Again this is JMHO; DYOR. I would love to hear what you guys think.
Regards.
NT.